— Know what they know.
Not Investment Advice

VCYT NASDAQ

Veracyte, Inc.
1W: +16.2% 1M: +34.1% 3M: +26.8% YTD: +6.6% 1Y: +56.9% 3Y: +83.8% 5Y: +23.6%
$45.03
-0.16 (-0.35%)
 
Weekly Expected Move ±13.5%
$28 $33 $38 $44 $49
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Buy · Power 74 · $3.6B mcap · 79M float · 1.23% daily turnover · Short 69% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$517M +16.0% ▲
5Y CAGR: +34.5%
Gross Profit
$360M +20.8% ▲
5Y CAGR: +36.5%
Operating Income
$74M +359.4% ▲
Net Income
$66M +174.9% ▲
EPS (Diluted)
$0.82 +164.5% ▲
EBITDA
$90M +82.1% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$220M$297M$361M$446M$517M
YoY Growth+86.8%+35.1%+21.8%+23.5%+16.0%
Cost of Revenue$74M$102M$113M$148M$157M
Gross Profit$145M$195M$248M$298M$360M
Gross Margin66.1%65.7%68.7%66.9%69.6%
R&D Expenses$30M$41M$57M$69M$71M
SG&A Expenses$181M$174M$184M$206M$211M
Operating Expenses$227M$236M$334M$282M$286M
Operating Income-$82M-$41M-$86M$16M$74M
Operating Margin-37.3%-13.9%-23.8%3.6%14.3%
Interest Expense$241K$198K$15K$2K$0
Income Before Tax-$82M-$36M-$77M$26M$68M
Tax Expense-$6M$133K-$2M$2M$2M
Net Income-$76M-$37M-$74M$24M$66M
Net Margin-34.4%-12.3%-20.6%5.4%12.8%
EPS (Diluted)$-1.11$-0.51$-1.02$0.31$0.82
EBITDA-$60M-$7M-$49M$49M$90M
Shares Outstanding68M72M73M78M81M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms